Elutia Inc. (ELUT)vsMerck & Company Inc (MRK)
ELUT
Elutia Inc.
$0.75
-1.15%
HEALTHCARE · Cap: $36.36M
MRK
Merck & Company Inc
$146.91
-2.27%
HEALTHCARE · Cap: $368.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 555091% more annual revenue ($67.38B vs $12.14M). ELUT leads profitability with a 426.9% profit margin vs 3.6%. MRK earns a higher WallStSmart Score of 44/100 (D).
ELUT
Avoid35
out of 100
Grade: F
MRK
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-0.0%
Fair Value
$0.90
Current Price
$0.75
$0.15 premium
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$146.91
$62.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 221 in profit
Keeps 427 of every $100 in revenue as profit
Reasonable price relative to book value
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 11.6%
Negative free cash flow — burning cash
Trading at 8.6x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ELUT
The strongest argument for ELUT centers on Return on Equity, Profit Margin, Price/Book. Profitability is solid with margins at 426.9% and operating margin at -243.1%.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : ELUT
The primary concerns for ELUT are EPS Growth, Market Cap, Revenue Growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
ELUT profiles as a declining stock while MRK is a value play — different risk/reward profiles.
ELUT carries more volatility with a beta of 0.92 — expect wider price swings.
MRK is growing revenue faster at 4.7% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 35/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Elutia Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?